Tiziano Bandiera

Via Morego 30
Genoa, 16163, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications

Exposure of dams to Elexacaftor/ Tezacaftor/Ivacaftor during pregnancy and breastfeeding induces reversible alterations in newborn wild type CD-1 mice.

Exposure of dams to Elexacaftor/ Tezacaftor/Ivacaftor during pregnancy and breastfeeding induces reversible alterations in newborn wild type CD-1 mice.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: September 09, 2025

Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors.

Molecular targeting of the deubiquitinase USP14 to circumvent cisplatin resistance in ovarian carcinoma and identification of novel inhibitors.

Journal: Cancer drug resistance (Alhambra, Calif.)
Published: April 16, 2025

Rational optimization of D3R/GSK-3β dual target-directed ligands as potential treatment for bipolar disorder: Design, synthesis, X-ray crystallography, molecular dynamics simulations, in vitro ADME, and in vivo pharmacokinetic studies.

Rational optimization of D3R/GSK-3β dual target-directed ligands as potential treatment for bipolar disorder: Design, synthesis, X-ray crystallography, molecular dynamics simulations, in vitro ADME, and in vivo pharmacokinetic studies.

Journal: European journal of medicinal chemistry
Published: March 03, 2025

Design of multi-target peptide modulators for protein chaperone networks.

Design of multi-target peptide modulators for protein chaperone networks.

Journal: Structure (London, England : 1993)
Published: February 28, 2025

Target Identification with Live-Cell Photoaffinity Labeling and Mechanism of Action Elucidation of ARN23765, a Highly Potent CFTR Corrector.

Target Identification with Live-Cell Photoaffinity Labeling and Mechanism of Action Elucidation of ARN23765, a Highly Potent CFTR Corrector.

Journal: Journal of medicinal chemistry
Published: February 10, 2025

Pharmaceutical and biomedical challenges for crew autonomy in health preservation during future exploration missions.

Pharmaceutical and biomedical challenges for crew autonomy in health preservation during future exploration missions.

Journal: Communications medicine
Published: January 29, 2025

Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators.

Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators.

Journal: Frontiers in pharmacology
Published: September 10, 2024

Human Multi-Lineage Liver Organoid Model Reveals Impairment of CYP3A4 Expression upon Repeated Exposure to Graphene Oxide.

Human Multi-Lineage Liver Organoid Model Reveals Impairment of CYP3A4 Expression upon Repeated Exposure to Graphene Oxide.

Journal: Cells
Published: July 08, 2024

Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.

Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.

Journal: European journal of medicinal chemistry
Published: June 12, 2024

Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS).

Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS).

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: February 28, 2024

NAPE-PLD is target of thiazide diuretics.

NAPE-PLD is target of thiazide diuretics.

Journal: Cell chemical biology
Published: October 21, 2023

Small Molecules Targeting DNA Polymerase Theta (POLθ) as Promising Synthetic Lethal Agents for Precision Cancer Therapy.

Small Molecules Targeting DNA Polymerase Theta (POLθ) as Promising Synthetic Lethal Agents for Precision Cancer Therapy.

Journal: Journal of medicinal chemistry
Published: May 03, 2023
Showing 1-12 of 72

Last Updated: 09/26/2026